The Lancet. Infectious diseases
A 3-month clofazimine-rifapentine-containing regimen for drug-susceptible tuberculosis versus standard of care (Clo-Fast): a randomised, open-label, phase 2c clinical trial.
Sutezolid in combination with bedaquiline, delamanid, and moxifloxacin for pulmonary tuberculosis (PanACEA-SUDOCU-01): a prospective, open-label, randomised, phase 2b dose-finding trial.
Delpazolid in combination with bedaquiline, delamanid, and moxifloxacin for pulmonary tuberculosis (PanACEA-DECODE-01): a prospective, randomised, open-label, phase 2b, dose-finding trial.
Representativeness and adverse event reporting in late-phase clinical trials for rifampin-susceptible tuberculosis: a systematic review.
Biomarkers for tuberculosis disease activity, cure, and relapse.
New antituberculosis drugs, regimens, and adjunct therapies: needs, advances, and future prospects.
Shortening treatment of tuberculosis: lessons from fluoroquinolone trials.
High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial.
STREAM: a pragmatic and explanatory trial for MDR-TB treatment.
Drug-resistant tuberculosis: time for visionary political leadership.
